Germline pharmacogenetics of paclitaxel for cancer treatment

Pharmacogenomics

Volumn 14, Issue 9, 2013, Pages 1065-1084

  Hertz, Daniel L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

ABCB1; CYP2C8; CYP3A4 5; FGD4; GWAS; Paclitaxel; Personalized medicine; Pharmacogenetics; Single nucleotide polymorphism; SNP; TUBB

Indexed keywords

BETA TUBULIN; CYTOCHROME P450 1B1; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; PREGNANE X RECEPTOR;

ABCB1 GENE; ABCB2 GENE; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CYP1B1 GENE; CYP2C8 GENE; CYP3A GENE; CYP3A4 GENE; CYP3A5 GENE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERM LINE GENE THERAPY; HAPLOTYPE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE; OVERALL SURVIVAL; PHARMACOGENETICS; PREGNANE X RECEPTOR GENE; PUBLICATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B3 GENE;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOME-WIDE ASSOCIATION STUDY; GERM CELLS; HUMANS; NEOPLASMS; PACLITAXEL; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84880472182     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.90     Document Type: Review

References (95)

1. Mielke S, Sparreboom A, Steinberg SM et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin. Cancer Res. 11(13), 4843-4850 (2005).
2. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer. Biol. Ther. 4(8), 815-818 (2005).
3. Sonnichsen D, Liu Q, Schuetz E, Schuetz J, Pappo A, Relling M. Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther. 275(2), 566-575 (1995).
4. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int. J. Cancer 116(5), 824-829 (2005).
5. Sparreboom A, van Asperen J, Mayer U et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl Acad. Sci. USA 94(5), 2031-2035 (1997).
6. Ioannidis JP, Tarone R, McLaughlin JK. The false-positive to false-negative ratio in epidemiologic studies. Epidemiology 22(4), 450-456 (2011).
7. Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, Zhou SF. Human CYP2C8: Structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr. Drug Metab. 10(9), 1009-1047 (2009).
8. Hertz DL, Walko CM, Bridges AS et al. Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. Br. J. Clin. Pharmacol. 74(1), 197-200 (2012).
9. The International HapMap Project. Nature 426(6968), 789-796 (2003).
10. Rowbotham SE, Boddy AV, Redfern CPF, Veal GJ, Daly AK. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metab. Dispos. 38(8), 1261-1266 (2010).
11. Gr1. en H, Söderkvist P, Rosenberg P et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin. Pharmacol. Toxicol. 104(2), 130-137 (2009).
12. Bergmann TK, Brasch-Andersen C, Gr1. en H et al. Impact of CYP2C8*3 on paclitaxel clearance: A population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 11(2), 113-120 (2011).
13. de Graan AJ, Elens L, Sprowl JA et al. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-12- 3786 (2013) (Epub ahead of print).
14. Henningsson A, Marsh S, Loos WJ et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res. 11(22), 8097-8104 (2005).
15. Fransson MN, Gr1. en H, Litton J, Friberg LE. Influence of cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab. Dispos. 39(2), 247-255 (2011).
16. Marsh S, Somlo G, Li X et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7(5), 362-365 (2007).
17. Leskela S, Jara C, Leandro-Garcia L et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 11(2), 121-129 (2011).
18. Hertz DL, Roy S, Motsinger-Reif AA et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann. Oncol. 24(6), 1472-1478 (2013).
19. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in ovarian cancer. J. Clin. Oncol. 25(29), 4528-4535 (2007).
20. Ofverholm A, Einbeigi Z, Manouchehrpour S, Albertsson P, Skrtic S, Enerback C. The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity. Oncol. Lett. 1(1), 151-154 (2010).
21. Rizzo R, Spaggiari F, Indelli M et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res. Treat. 124(2), 593-598 (2010).
22. Bergmann TK, Brasch-Andersen C, Gr1. en H et al. Impact of ABCB1 variants on neutrophil depression: A pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin. Pharmacol. Toxicol. 110(2), 199-204 (2012).
23. Hertz DL, Motsinger-Reif AA, Drobish A et al. CYP2C8*3 predicts benefit-risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res. Treat. 134(1), 401-410 (2012).
24. Bergmann TK, Gr1. en H, Brasch-Andersen C et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur. J. Clin. Pharmacol. 67(7), 693-700 (2011
25. Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27(21), 3540-3546 (2009).
26. Jiang H, Zhong F, Sun L, Feng W, Huang Z, Tan X. Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8. Amino Acids 40(4), 1195-1204 (2011).
27. Dai D, Zeldin DC, Blaisdell JA et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7), 597-607 (2001).
28. Hichiya H, Tanaka-Kagawa T, Soyama A et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab. Dispos. 33(5), 630-636 (2005).
29. Saito Y, Katori N, Soyama A et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet. Genomics 17(7), 461-471 (2007).
30. Soyama A, Saito Y, Hanioka N et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24(12), 1427-1430 (2001).
31. Hanioka N, Matsumoto K, Saito Y, Narimatsu S. Functional characterization of CYP2C8.13 and CYP2C8.14: Catalytic activities toward paclitaxel. Basic Clin. Pharmacol. Toxicol. 107(1), 565-569 (2010).
32. Rodriguez-Antona C, Niemi M, Backman JT et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 8(4), 268-277 (2007).
33. Gr1. en H, Khan MS, Jakobsen-Falk I, Åvall-Lundqvist E, Peterson C. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer. J. Pharm. Sci. doi: 10.1002/jps.22680 (2011) (Epub ahead of print).
34. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin. Drug Metab. Toxicol. 2(2), 171-182 (2006).
35. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 54(1), 53-58 (1998).
36. Rahmioglu N, Heaton J, Clement G et al. Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet. Genomics 21(10), 642-651 (2011).
37. Zhou L, Yao F, Luan H et al. CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis. Tumor Biol. 34(2), 649-660 (2013).
38. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 42(4), 299-305 (2003).
39. Rodríguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem. Biophys. Res. Commun. 338(1), 299-305 (2005).
40. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011).
41. Nakajima Y, Yoshitani T, Fukushima-Uesaka H et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin. Pharmacol. Ther. 80(2), 179-191 (2006).
42. Maekawa K, Harakawa N, Yoshimura T et al. CYP3A4*16 and CYP3A4*18 alleles found in east Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab. Dispos. 38(12), 2100-2104 (2010).
43. Nakajima M, Fujiki Y, Kyo S et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J. Clin. Pharmacol. 45(6), 674-682 (2005).
44. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
45. Baker SD, Verweij J, Cusatis GA et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther. 85(2), 155-163 (2008).
46. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab. Pharmacokinet. 27(1), 85-105 (2012).
47. Chang H, Rha SY, Jeung HC et al. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol. Rep. 23(1), 271-278 (2010).
48. Chang H, Rha SY, Jeung HC et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann. Oncol. 20(2), 272-277 (2009).
49. Hemauer SJ, Nanovskaya TN, Abdel- Rahman SZ, Patrikeeva SL, Hankins GDV, Ahmed MS. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem. Pharmacol. 79(6), 921-925 (2010).
50. Jiko M, Yano I, Sato E et al. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int. J. Clin. Oncol. 12(4), 284-290 (2007).
51. Yamaguchi H, Hishinuma T, Endo N et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int. J. Gynecol. Cancer 16(3), 979-985 (2006).
52. Grau JJ, Caballero M, Campayo M et al. Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. Laryngoscope 119(8), 1484-1490 (2009).
53. Johnatty SE, Beesley J, Paul J et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin. Cancer Res. 14(17), 5594-5601 (2008).
54. Shitara K, Matsuo K, Ito S et al. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac. J. Cancer. Prev. 11(2), 447-452 (2010).
55. Sissung TM, Mross K, Steinberg SM et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer 42(17), 2893-2896 (2006).
56. Gow JM, Hodges LM, Chinn LW, Kroetz DL. Substrate-dependent effects of human ABCB1 coding polymorphisms. J. Pharmacol. Exp. Ther. 325(2), 435-442 (2008).
57. Kwon WS, Rha SY, Jeung H et al. G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Cancer Lett. 277(2), 155-163 (2009).
58. Gr1. en H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. MDR-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res. 12(3), 854-859 (2006).
59. Marsh S, King CR, McLeod HL, Paul J, Gifford G, Brown R. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin. Cancer Res. 12(13), 4127-4129 (2006).
60. Kim JW, Kim JH, Im SA et al. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology 83(4), 218-227 (2012).
61. Ludwig AH, Kupryjañczyk J. Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy? Clin. Cancer Res. 12(20), 6204-6204 (2006).
62. Kim HS, Kim M, Chung HH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study. Gynecol. Oncol. 113(2), 264-269 (2009).
63. Crouthamel MH, Wu D, Yang Z, Ho RJY. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J. Pharm. Sci. 95(12), 2767-2777 (2006).
64. Gr1. en H, Söderkvist P, Rosenberg P, Horvath G, Peterson C. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J. Pharm. Sci. 97(6), 2045-2048 (2008).
65. Takane H, Kobayashi D, Hirota T et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J. Pharmacol. Exp. Ther. 311(3), 1179-1187 (2004).
66. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: Implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol. 5(7), 703-729 (2009).
67. Lagas JS, Vlaming ML, van Tellingen O et al. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin. Cancer Res. 12(20), 6125-6132 (2006).
68. Sun N, Sun X, Chen B et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 65(3), 437-446 (2010).
69. Van De Steeg E, van Esch A, Wagenaar E et al. High impact of OATP1A/1B transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin. Cancer Res. 17(2), 294-301 (2011).
70. Takano M, Otani Y, Tanda M, Kawami M, Nagai J, Yumoto R. Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2. Drug Metab. Pharmacokinet. 24(5), 418-427 (2009).
71. Smith NF, Marsh S, Scott-Horton TJ et al. Variants in the SLCO1B3 gene: Interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther. 81(1), 76-82 (2007).
72. Burckhardt G, Burckhardt BC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb. Exp. Pharmacol. (201), 29-104 (2011).
73. Tian C, Ambrosone CB, Darcy KM et al. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A gynecologic oncology group study. Gynecol. Oncol. 124(3), 575-581 (2012).
74. Hasmats J, Kupershmidt I, Rodríguez-Antona C et al. Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. Gene 506(1), 62-68 (2012).
75. Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem. Pharmacol. 83(8), 1112-1126 (2012).
76. Lim YP, Liu CH, Shyu LJ, Huang JD. Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet. Genomics 15(5), 337-341 (2005).
77. Saeki M, Kurose K, Hasegawa R, Tohkin M. Functional analysis of genetic variations in the 5′-flanking region of the human MDR1 gene. Mol. Genet. Metab. 102(1), 91-98 (2011).
78. Berrieman HK, Lind MJ, Cawkwell L Do b-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol. 5(3), 158-164 (2004).
79. Leandro-Garcia LJ, Leskela S, Jara Sanchez C et al. Regulatory polymorphisms in b-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin. Cancer Res. 18(16), 4441-4448 (2012).
80. Leandro-García LJ, Leskelä S, Inglada-P1. rez L et al. Hematologic b-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. Cancer Res. 72(18), 4744-4752 (2012).
81. Gajjar K, Martin-Hirsch PL, Martin FL. CYP1B1 and hormone-induced cancer. Cancer Lett. 324(1), 13-30 (2012).
82. Bournique B, Lemari1. A. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab. Dispos. 30(11), 1149-1152 (2002).
83. Pastina I, Giovannetti E, Chioni A et al. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in castration-resistant prostate cancer (CRPC) patients. BMC Cancer 10, 511 (2010).
84. Figg WD, Li H, Sissung T et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 99(5), 1047-1055 (2007).
85. Sissung TM, Danesi R, Price DK et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther. 7(1), 19-26 (2008).
86. Sucheston L, Zhao H, Yao S et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG Phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res. Treat. 130(3), 993-1002 (2011).
87. Sato Y, Yamamoto N, Kunitoh H et al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J. Thorac. Oncol. 6(1), 132-138 (2011).
88. Schneider BP, Li L, Miller K et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. ASCO Meeting Abstracts 29(15 Suppl.), S1000 (2011).
89. Bergmann TK, Vach W, Feddersen S et al. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol. 52(4), 871-874 (2012).
90. Baldwin RM, Owzar K, Zembutsu H et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin. Cancer Res. 18(18), 5099-5109 (2012).
91. Delague V, Jacquier A, Hamadouche T et al. Mutations in FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal recessive Charcot-Marie-Tooth type 4H. Am. J. Hum. Genet. 81(1), 1-16 (2007).
92. Wheeler HE, Gamazon ER, Wing C et al. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy. Clin. Cancer Res. 19(2), 491-499 (2012).
93. Njiaju UO, Gamazon ER, Gorsic LK et al. Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet. Genomics 22(7), 498-507 (2012).
94. O'Brien C, Cavet G, Pandita A et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2- amplified breast cancer. Cancer Res. 68(13), 5380-5389 (2008).
95. Niu N, Schaid D, Abo R et al. Genetic association with overall survival of taxane-treated lung cancer patients-a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study. BMC Cancer 12(1), 422 (2012).